BeOne Medicines Ltd. — Director's Dealing 2019

Apr 11, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BeiGene, Ltd. (BGNE)
CIK: 0001651308
Period of Report: 2019-04-08

Reporting Person: Huang Jane (CMO, Hematology)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-04-08	American Depositary Shares	M	14130	$29.49	Acquired	14130	Direct
2019-04-08	American Depositary Shares	S	800	$140.4875	Disposed	13330	Direct
2019-04-08	American Depositary Shares	S	3439	$141.8033	Disposed	9891	Direct
2019-04-08	American Depositary Shares	S	6159	$142.7277	Disposed	3732	Direct
2019-04-08	American Depositary Shares	S	2304	$143.7207	Disposed	1428	Direct
2019-04-08	American Depositary Shares	S	1281	$144.9004	Disposed	147	Direct
2019-04-08	American Depositary Shares	S	147	$145.9399	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-04-08	Share Option (Right to Buy)	$2.27	M	183690	Acquired	2026-09-02	Ordinary Shares (183690.0)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares	271621	Direct

Footnotes

F1: Each American Depositary Share ("ADS") represents 13 Ordinary Shares.

F2: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $140.10 to $141.06, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $141.30 to $142.27, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $142.32 to $143.25, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.32 to $144.24, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.49 to $145.15, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price.

F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $145.67 to $146.04, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price.

F9: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our ADSs on the date of grant, as each ADS represents 13 ordinary shares.

F10: These securities vest over a four-year period as follows: 25% on the first anniversary of September 2, 2016 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events.